Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
EMERYVILLE, Calif., May 10, 2017 -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it expects revenue related to its Vitamin E partnership with Nenter to more than double based on the current success of the program. During 2016, the company shipped approximately $9 million of farnesene to Nenter for conversion to Vitamin E and expects 2017 shipments to Nenter to be about $20 million.
Success with Nenter on Vitamin E
Amyris and Nenter have a strong partnership and commitment to grow together, supplying high performing Vitamin E oil to the global nutraceuticals market. The commercialization phase of this partnership has started very strong and is an exclusive commitment between the two companies for the commercial production of Vitamin E.
Exclusive License Agreement with DSM on Vitamin A
The company also announced today that as part of its focus on growing its relationship with Koninklijke DSM N.V. (Royal DSM)(AEX:DSM.AS) it is entering into an exclusive licensing agreement for Vitamin A within the nutraceuticals market. This relationship is focused on a fast-track to market for the production and commercialization of low-cost supply of Vitamin A.
“Nenter’s investment and commitment to the Vitamin E market has proved to be an ideal partnership for growth by both companies,” said John Melo, Amyris President & CEO. “We are excited by their early commercialization results. This is a great example of combining our technology platform with their capabilities to deliver better chemistry. We plan to replicate this success with DSM on Vitamin A and expect a successful program and delivery of product before the end of 2019.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Amyris Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the company’s anticipated 2017 Vitamin E-related sales to Nenter, its expectations regarding entering into an exclusive licensing agreement for Vitamin A with Royal DSM within the nutraceuticals market with fast-track to market for the production and commercialization of the product with low-cost supply, and the company’s belief that it will be able to provide delivery of Vitamin A to Royal DSM before the end of 2019) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]
